A small company can now advance its psychedelic into phase 3. Here’s why that matters to other psychedelic biotechs. A small ...
Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...
5d
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...
The U.S. Space Force has selected SpaceX and United Launch Alliance to perform the first seven launches under the National Security Space Launch Program, or NSSL, Phase 3 Lane 2 contracts, Breaking ...
Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met their co-primary endpoints in adults with moderate to severe plaque ...
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...
When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in November, the British biotech sounded confident that the latest readout set ...
Research into clinical uses for psychedelics has proliferated in recent years, but despite the constant stream of "psychedelic renaissance" news, the vast majority of studies remain in early, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Use of alternative endpoints in phase 3 oncology trials ...
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing secondary and exploratory biomarker endpoints, the biotech has pulled the plug on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback